

Table 2. Estimated patient numbers and cost†

	Year 1	Year 2	Year 3
Scenario with dostarlimab			
Dostarlimab	20 patients ¶¶	20 patients ¶¶	20 patients ¶¶
Scenario without dostarlimab			
SCRT + surgery	4 patients £76,529	4 patients £76,529	4 patients £76,529
SCRT + surgery + adjuvant chemo (¶¶-¶¶*)	4 patients ¶¶-¶¶	4 patients ¶¶-¶¶	4 patients ¶¶-¶¶
LCCRT + surgery	4 patients ¶¶	4 patients ¶¶	4 patients ¶¶
LCCRT + surgery + adjuvant chemo (¶¶-¶¶*)	4 patients ¶¶-¶¶	4 patients ¶¶-¶¶	4 patients ¶¶-¶¶
Surgery + adjuvant chemo (¶¶-¶¶*)	4 patients ¶¶-¶¶	4 patients ¶¶-¶¶	4 patients ¶¶-¶¶
Total cost of scenario without dostarlimab	¶¶-¶¶	¶¶-¶¶	¶¶-¶¶
Budget impact	¶¶-¶¶	¶¶-¶¶	¶¶-¶¶

LCCRT; long-course chemoradiotherapy, SCRT; short-course radiotherapy

*Range based on cheapest option (3-month cycle CAPOX) and most expensive option (6-month cycle FOLFOX) with associated administration costs per patient.

†may not compute due to rounding

¶¶commercial in confidence figure removed